ArticleFrontiers in pharmacology2026
Posaconazole mitigates α-amanitin-induced liver injury by inhibiting STT3B-mediated glycosylation and cellular uptake.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mushroom poisoning caused by Methods: Posaconazole was identified through STT3B-focused virtual screening followed by Results: Posaconazole robustly protected human hepatocytes from AMA-induced toxicity in both 2D and 3D cultures. In a lethal mouse model, post-exposure treatment with posaconazole significantly attenuated AMA-induced liver injury and improves survival, achieving efficacy comparable to prior candidate. Mechanistically, posaconazole potentially inhibited the STT3B-mediated N-glycosylation, thereby suppressing down-stream sialylation. The genetic ablation of sialyltransferase ST6GAL1 confirmed that reduced sialylation limits cellular AMA uptake and confers resistance to toxicity. Conclusion: Our work unveils a critical glycosylation-dependent pathway for AMA toxicity and nominates posaconazole as a clinically translatable, host-directed therapeutic candidate for the treatment of lethal Amanita phalloides poisoning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.